# MT2022-01: MSCs for ALD

> **NCT06030648** · PHASE1 · SUSPENDED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 10 (estimated)

## Conditions studied

- Cerebral Adrenoleukodystrophy

## Interventions

- **BIOLOGICAL:** Mesenchymal stem cells (IV-MSC)

## Key facts

- **NCT ID:** NCT06030648
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-08-28
- **Primary completion:** 2026-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** Awaiting supplies
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030648, "MT2022-01: MSCs for ALD". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06030648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*